These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 9381260)

  • 1. [Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Spanish Group on Gaucher's Disease].
    Pérez-Calvo JI; Giraldo P; Giralt M
    Sangre (Barc); 1997 Jun; 42(3):189-94. PubMed ID: 9381260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics.
    Giraldo P; Pocoví M; Pérez-Calvo J; Rubio-Félix D; Giralt M
    Haematologica; 2000 Aug; 85(8):792-9. PubMed ID: 10942924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Type I Gaucher's disease: clinical, evolutive and therapeutic features in 8 cases].
    Giraldo P; Pérez-Calvo J; Cortés T; Civeira F; Rubio-Félix D
    Sangre (Barc); 1994 Feb; 39(1):3-7. PubMed ID: 8197516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alglucerase. A review of its therapeutic use in Gaucher's disease.
    Whittington R; Goa KL
    Drugs; 1992 Jul; 44(1):72-93. PubMed ID: 1379912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical characteristics of type I Gaucher's disease in Spain. Preliminary results of national survey. Spanish Group on Gaucher's Disease].
    Giraldo P; Pérez-Calvo JI; Giralt M; Pocovi M
    Med Clin (Barc); 1997 Nov; 109(16):619-22. PubMed ID: 9463135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic targets in Gaucher's disease].
    Giraldo P; Roca M
    Med Clin (Barc); 2011 Sep; 137 Suppl 1():46-9. PubMed ID: 22230126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease.
    Hollak CE; Aerts JM; Goudsmit R; Phoa SS; Ek M; van Weely S; von dem Borne AE; van Oers MH
    Lancet; 1995 Jun; 345(8963):1474-8. PubMed ID: 7769902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience.
    Grigorescu Sido P; Drugan C; Cret V; Al-Kzouz C; Denes C; Coldea C; Zimmermann A
    J Inherit Metab Dis; 2007 Oct; 30(5):783-9. PubMed ID: 17703370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A less costly regimen of alglucerase to treat Gaucher's disease.
    Figueroa ML; Rosenbloom BE; Kay AC; Garver P; Thurston DW; Koziol JA; Gelbart T; Beutler E
    N Engl J Med; 1992 Dec; 327(23):1632-6. PubMed ID: 1435900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
    Weinreb NJ; Camelo JS; Charrow J; McClain MR; Mistry P; Belmatoug N;
    Mol Genet Metab; 2021 Feb; 132(2):100-111. PubMed ID: 33485799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemostatic abnormalities in treatment-naïve patients with Type 1 Gaucher's disease.
    Mitrovic M; Antic D; Elezovic I; Janic D; Miljic P; Sumarac Z; Nikolic T; Suvajdzic N
    Platelets; 2012; 23(2):143-9. PubMed ID: 21767238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment.
    Zimran A; Elstein D; Kannai R; Zevin S; Hadas-Halpern I; Levy-Lahad E; Cohen Y; Horowitz M; Abrahamov A
    Am J Med; 1994 Jul; 97(1):3-13. PubMed ID: 8030654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Gaucher's disease ].
    Belmatoug N; Caubel I; Stirnemann J; Billette de Villemeur T
    J Soc Biol; 2002; 196(2):141-9. PubMed ID: 12360743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease.
    Hollak CE; Corssmit EP; Aerts JM; Endert E; Sauerwein HP; Romijn JA; van Oers MH
    Am J Med; 1997 Sep; 103(3):185-91. PubMed ID: 9316550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources.
    Grabowski GA; Barton NW; Pastores G; Dambrosia JM; Banerjee TK; McKee MA; Parker C; Schiffmann R; Hill SC; Brady RO
    Ann Intern Med; 1995 Jan; 122(1):33-9. PubMed ID: 7985893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment.
    Weinreb NJ; Goldblatt J; Villalobos J; Charrow J; Cole JA; Kerstenetzky M; vom Dahl S; Hollak C
    J Inherit Metab Dis; 2013 May; 36(3):543-53. PubMed ID: 22976765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subtotal splenectomy for Gaucher's disease: a follow-up study.
    Morgenstern L; Verham R; Weinstein I; Phillips EH
    Am Surg; 1993 Dec; 59(12):860-5. PubMed ID: 8256944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months.
    Pastores GM; Sibille AR; Grabowski GA
    Blood; 1993 Jul; 82(2):408-16. PubMed ID: 8392397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement therapy for Gaucher disease in Australia.
    Goldblatt J; Szer J; Fletcher JM; McGill J; Rowell JA; Wilson M
    Intern Med J; 2005 Mar; 35(3):156-61. PubMed ID: 15737135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.